Study of peripheral blood lymphocyte subset distribution and IL-2 receptor (IL-2 R) p55-p75 subunit expression in patients with cancer of different sites.
The aim of the study was to evaluate the subset distribution and the IL-2 R p55-p75 subunit expression on unstimulated and phytohemagglutinin (PHA)-stimulated (at 3-d) peripheral blood mononuclear cells (PBMC), of patients with solid cancers of different sites. Indeed the expression of the two subunits of IL-2 R is an essential prerequisite for the action of the IL-2 on CD8+, CD16+ lymphocytes as effectors in antitumor activity (LAK-cell). The subset distribution (CD3, CD4, CD8, CD16, DR) was assessed by cytofluorometry with specific monoclonal antibodies (MAbs); the p55 (CD25) and p75 subunit expression was evaluated by specific MAb (OKT26a and anti-p75). Ninety patients with advanced cancer (mainly non-small cell lung cancer [NSCLC], head and neck cancer, and gynecological cancer; mean age 55 yr; range 27-80) were studied. Thirty-five age- and sex-matched healthy subjects were studied as controls. Our data show that there is no significant difference in the subset distribution between cancer patients and controls. Furthermore, no difference has been found in the expression of p55 subunits on unstimulated PBMC between cancer patients and controls. No difference has been found in the expression of both p55 and p75 subunits on PHA-stimulated PBMC between cancer patients and controls. Our results can support the rationale for further clinical trials with IL-2 in solid malignancies.
Mantovani
G
G
Department of Medical Oncology, University of Cagliari, Italy.
Macciò
A
A
Lai
P
P
Turnu
E
E
Del Giacco
G S
GS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D005260:Female; D005434:Flow Cytometry; D005833:Genital Neoplasms, Female / Q000628:therapy; D006258:Head and Neck Neoplasms / Q000628:therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D008175:Lung Neoplasms / Q000628:therapy; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D010835:Phytohemagglutinins; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D016176:T-Lymphocyte Subsets
D010835:Phytohemagglutinins; D015375:Receptors, Interleukin-2